MDxHealth SA (MDXH.BR) Stock Fundamental Analysis
Europe - Euronext Brussels - EBR:MDXH - BE0974461940 - Common Stock
3.02 EUR
-0.12 (-3.76%)
MDXH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 85 industry peers in the Biotechnology industry. Both the profitability and financial health of MDXH have multiple concerns. MDXH is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year MDXH has reported negative net income.
1.2 Ratios
- The Return On Assets of MDXH (-51.61%) is worse than 63.64% of its industry peers.
- MDXH has a Return On Equity of -393.48%. This is in the lower half of the industry: MDXH underperforms 75.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -51.61% | ||
| ROE | -393.48% | ||
| ROIC | N/A |
ROA(3y)-55.15%
ROA(5y)-64.23%
ROE(3y)-343.17%
ROE(5y)-262.12%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- MDXH has a better Gross Margin (59.66%) than 64.94% of its industry peers.
- In the last couple of years the Gross Margin of MDXH has declined.
- MDXH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 59.66% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-6.79%
2. Health
2.1 Basic Checks
- MDXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
- MDXH has more shares outstanding than it did 1 year ago.
- Compared to 1 year ago, MDXH has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -3.05, we must say that MDXH is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -3.05, MDXH is not doing good in the industry: 71.43% of the companies in the same industry are doing better.
- MDXH has a Debt/Equity ratio of 2.17. This is a high value indicating a heavy dependency on external financing.
- MDXH has a worse Debt to Equity ratio (2.17) than 75.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.17 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.05 |
ROIC/WACCN/A
WACC6.93%
2.3 Liquidity
- MDXH has a Current Ratio of 2.43. This indicates that MDXH is financially healthy and has no problem in meeting its short term obligations.
- With a Current ratio value of 2.43, MDXH perfoms like the industry average, outperforming 44.16% of the companies in the same industry.
- A Quick Ratio of 2.27 indicates that MDXH has no problem at all paying its short term obligations.
- MDXH's Quick ratio of 2.27 is in line compared to the rest of the industry. MDXH outperforms 44.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.43 | ||
| Quick Ratio | 2.27 |
3. Growth
3.1 Past
- The earnings per share for MDXH have decreased strongly by -16.81% in the last year.
- MDXH shows a strong growth in Revenue. In the last year, the Revenue has grown by 66.59%.
- Measured over the past years, MDXH shows a decrease in Revenue. The Revenue has been decreasing by -1.77% on average per year.
EPS 1Y (TTM)-16.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
Revenue 1Y (TTM)66.59%
Revenue growth 3Y46.47%
Revenue growth 5Y-1.77%
Sales Q2Q%73.48%
3.2 Future
- MDXH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.91% yearly.
- The Revenue is expected to grow by 27.69% on average over the next years. This is a very strong growth
EPS Next Y-6519.8%
EPS Next 2Y-619.83%
EPS Next 3Y-49.87%
EPS Next 5Y51.91%
Revenue Next Year84.81%
Revenue Next 2Y47.5%
Revenue Next 3Y43.11%
Revenue Next 5Y27.69%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- MDXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year MDXH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- MDXH's earnings are expected to decrease with -49.87% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-619.83%
EPS Next 3Y-49.87%
5. Dividend
5.1 Amount
- No dividends for MDXH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MDxHealth SA / MDXH.BR FAQ
Can you provide the ChartMill fundamental rating for MDxHealth SA?
ChartMill assigns a fundamental rating of 2 / 10 to MDXH.BR.
What is the valuation status of MDxHealth SA (MDXH.BR) stock?
ChartMill assigns a valuation rating of 0 / 10 to MDxHealth SA (MDXH.BR). This can be considered as Overvalued.
How profitable is MDxHealth SA (MDXH.BR) stock?
MDxHealth SA (MDXH.BR) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for MDXH stock?
The Earnings per Share (EPS) of MDxHealth SA (MDXH.BR) is expected to decline by -6519.8% in the next year.